 |
Adam Bonislawski is the editor of GenomeWeb's ProteoMonitor. He covers proteomics and life science mass spectrometry. E-mail Adam Bonislawski and follow his GenomeWeb Twitter account at @ProteoMonitor. |
Multi-Site Validation Study Published Supporting Astute Medical's NephroCheck AKI Test
February 08, 2013
Multi-Site Validation Study Published Supporting Astute Medical's NephroCheck AKI Test
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Astute Medical Launches European Sales of Nephrocheck AKI Risk Assessment Test
October 19, 2012 / ProteoMonitor - BG Medicine Files 510(k) for Automated Galectin-3 Test on Abbot Architect Platform
July 27, 2012 / ProteoMonitor - Astute Medical Completes $40M Series C Funding Round
June 8, 2012 / ProteoMonitor - Columbia Team IDs Two Protein Markers to Improve Prediction of Acute Kidney Injury, Adverse Effects
January 13, 2012 / ProteoMonitor - Astute Medical Raises $13M for Protein Biomarker Dx Development
March 11, 2011 / ProteoMonitor